Melatonin attenuates morphine-induced conditioned place preference in Wistar rats.

Fahad S Alshehri, Badrah S Alghamdi, Alqassem Y Hakami, Abdullah A Alshehri, Yusuf S Althobaiti
Author Information
  1. Fahad S Alshehri: Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. ORCID
  2. Badrah S Alghamdi: Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. ORCID
  3. Alqassem Y Hakami: College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  4. Abdullah A Alshehri: Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  5. Yusuf S Althobaiti: Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.

Abstract

PURPOSE: Morphine is the predominantly used drug for postoperative and cancer pain management. However, the abuse potential of morphine is the primary disadvantage of using opioids in pain management. Melatonin is a neurohormone synthesized in the pineal gland and is involved in circadian rhythms in mammals, as well as other physiological functions. Melatonin provenly attenuates alcohol-seeking and relapse behaviors in rats. Therefore, we aimed to investigate the involvement of the melatonergic system in attenuating morphine dependence.
MATERIALS AND METHODS: Male Wistar rats were divided into three groups: control, morphine, and morphine + melatonin. Animals were habituated for 3 days, and the initial preference was evaluated. Following the initial preference, the control group received the vehicle and was placed for a 45-min session in the assigned chamber every day, alternating between the two chambers, for 8 days. The morphine group received a morphine injection (5 mg/kg, IP) and was placed for a 45-min session in the white chamber, for a total of four sessions. The morphine + melatonin group received the morphine injection (5 mg/kg, IP) for a total of four sessions over an 8-day period. In the posttest session, the control and morphine groups received a vehicle injection 30 min before placement in the conditioned place preference (CPP). The morphine + melatonin group received a single injection of melatonin (50 mg/kg, IP) 30 min before the preference test.
RESULTS: Statistical analysis revealed that repeated administration of morphine for four sessions produced a significant increase in the CPP score in the morphine group compared to the control group. However, a single melatonin injection administered 30 min before the posttest attenuated morphine-seeking behavior and reduced morphine-induced place preference.
CONCLUSION: These findings provide novel evidence for the role of the melatonergic system as a potential target in modulating morphine-seeking behavior.

Keywords

References

  1. Synapse. 1993 Jul;14(3):243-5 [PMID: 8211708]
  2. Life Sci. 2006 Aug 1;79(10):972-80 [PMID: 16750225]
  3. J Neurosci. 2002 Jul 1;22(13):5769-76 [PMID: 12097530]
  4. Brain Res. 1980 Nov 10;201(1):240-4 [PMID: 7417837]
  5. J Neurosci. 1995 Mar;15(3 Pt 2):2396-406 [PMID: 7891175]
  6. Synapse. 2003 Jun 1;48(3):154-6 [PMID: 12645041]
  7. Sleep. 2010 Jun;33(6):833-40 [PMID: 20550025]
  8. J Vis Exp. 2018 Nov 6;(141): [PMID: 30474645]
  9. Eur J Neurosci. 2000 Dec;12(12):4206-14 [PMID: 11122332]
  10. Neurosci Lett. 2012 Jan 6;506(1):79-83 [PMID: 22056485]
  11. Neuropsychopharmacology. 2005 Jun;30(6):1128-37 [PMID: 15688084]
  12. Brain Behav. 2021 Dec;11(12):e2397 [PMID: 34710287]
  13. Chronobiol Int. 2012 Feb;29(1):35-42 [PMID: 22217099]
  14. Brain Res Mol Brain Res. 2005 May 20;136(1-2):45-53 [PMID: 15893586]
  15. Brain Res Bull. 2005 Jan 30;64(6):471-9 [PMID: 15639542]
  16. Psychopharmacology (Berl). 2017 Jun;234(11):1741-1748 [PMID: 28246896]
  17. Exp Mol Med. 2018 Nov 14;50(11):1-12 [PMID: 30429454]
  18. Anesth Analg. 2017 Nov;125(5):1769-1778 [PMID: 29049121]
  19. BMC Anesthesiol. 2015 Jan 28;15:12 [PMID: 25745356]
  20. Cell Mol Neurobiol. 2001 Dec;21(6):605-16 [PMID: 12043836]
  21. Brain Res. 1982 Aug 19;246(1):161-3 [PMID: 7127086]
  22. Hippocampus. 2002;12(2):165-73 [PMID: 12000116]
  23. Pharmacol Biochem Behav. 2003 Feb;74(3):573-8 [PMID: 12543221]
  24. Front Pharmacol. 2011 Aug 08;2:46 [PMID: 21852973]
  25. Anesthesiology. 2003 Jul;99(1):160-5 [PMID: 12826856]
  26. Neuropsychopharmacology. 2015 Dec;40(13):2897-906 [PMID: 25994077]
  27. Inflammation. 1994 Jun;18(3):293-9 [PMID: 8088925]
  28. J Biomed Sci. 2000 Nov-Dec;7(6):444-58 [PMID: 11060493]
  29. Pharmacol Biochem Behav. 2013 Sep;110:112-6 [PMID: 23827650]
  30. Acta Pharmacol Sin. 2002 Sep;23(9):860-4 [PMID: 12230959]
  31. Br J Anaesth. 2003 Apr;90(4):504-7 [PMID: 12644425]
  32. Ann N Y Acad Sci. 1999 Jun 29;877:461-85 [PMID: 10415665]
  33. Brain Res. 1999 Jul 10;834(1-2):178-81 [PMID: 10407111]
  34. Basic Clin Pharmacol Toxicol. 2004 Aug;95(2):53-8 [PMID: 15379780]
  35. Curr Pain Headache Rep. 2018 Feb 23;22(3):16 [PMID: 29476358]
  36. Int J Mol Med. 2019 Feb;43(2):791-806 [PMID: 30569162]
  37. Cell Tissue Res. 2002 Jul;309(1):151-62 [PMID: 12111545]
  38. Mol Brain. 2018 Jun 28;11(1):35 [PMID: 29954440]
  39. Addict Biol. 2011 Oct;16(4):580-90 [PMID: 21635669]
  40. Br J Anaesth. 1999 Jun;82(6):875-80 [PMID: 10562782]
  41. Dan Medicinhist Arbog. 2005;33:171-84 [PMID: 17152761]
  42. Eur J Neurosci. 2002 Sep;16(5):921-9 [PMID: 12372028]
  43. Curr Mol Pharmacol. 2021;14(2):150-164 [PMID: 32316905]
  44. Chin Med J (Engl). 2001 Mar;114(3):297-302 [PMID: 11780318]
  45. Emerg Health Threats J. 2012;5: [PMID: 22529876]
  46. Curr Top Med Chem. 2002 Feb;2(2):181-97 [PMID: 11899100]
  47. Curr Opin Psychiatry. 2021 Jul 1;34(4):405-412 [PMID: 33901060]
  48. Behav Brain Res. 2002 Nov 15;136(2):389-97 [PMID: 12429400]
  49. Life Sci. 1997;60(2):PL23-9 [PMID: 9000122]
  50. Exp Clin Psychopharmacol. 2008 Oct;16(5):405-16 [PMID: 18837637]
  51. Neuroendocrinology. 1983 Jul;37(1):41-7 [PMID: 6684217]
  52. J Pineal Res. 2007 Apr;42(4):323-9 [PMID: 17439548]
  53. Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):153-61 [PMID: 16918717]
  54. FASEB J. 1996 Jun;10(8):891-6 [PMID: 8666166]
  55. Drug Alcohol Depend. 1991 Jan;27(1):7-17 [PMID: 2029860]
  56. Nat Clin Pract Neurol. 2008 Aug;4(8):436-47 [PMID: 18628753]
  57. Int J Neurosci. 2012 Mar;122(3):154-63 [PMID: 22050217]
  58. Alcohol Alcohol. 2010 Jul-Aug;45(4):303-11 [PMID: 20554694]
  59. Br J Pharmacol. 2006 Jan;147 Suppl 1:S153-62 [PMID: 16402099]
  60. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9377-81 [PMID: 15967985]
  61. Fundam Clin Pharmacol. 2021 Feb;35(1):25-39 [PMID: 32415694]
  62. Behav Brain Res. 2011 Jan 1;216(1):159-65 [PMID: 20655954]
  63. Drug Alcohol Depend. 2009 Jul 1;103(1-2):74-83 [PMID: 19419821]
  64. Iran J Med Sci. 2015 May;40(3):240-7 [PMID: 25999624]
  65. Recent Pat CNS Drug Discov. 2009 Jan;4(1):61-9 [PMID: 19149715]
  66. Acta Biochim Pol. 2003;50(4):1129-46 [PMID: 14740000]
  67. J Pineal Res. 2005 Sep;39(2):99-104 [PMID: 16098085]
  68. Neurosci Lett. 1993 Apr 30;153(2):232-6 [PMID: 8392157]
  69. Mol Cells. 2016 Sep;39(9):645-53 [PMID: 27506251]
  70. Curr Top Behav Neurosci. 2010;3:29-71 [PMID: 21161749]
  71. Eur J Pharmacol. 2000 Dec 15;409(3):279-89 [PMID: 11108822]
  72. Anesth Analg. 2000 Aug;91(2):473-9 [PMID: 10910871]
  73. Support Care Cancer. 2002 Jan;10(1):13-35 [PMID: 11777184]
  74. World Psychiatry. 2019 Jun;18(2):231-232 [PMID: 31059614]
  75. Life Sci. 2002 Sep 13;71(17):2067-70 [PMID: 12175899]
  76. Biol Psychiatry. 2009 May 15;65(10):905-12 [PMID: 19135652]
  77. Behav Brain Res. 2018 Jul 16;347:368-376 [PMID: 29604365]
  78. Alcohol Clin Exp Res. 2003 Oct;27(10):1592-8 [PMID: 14574229]

MeSH Term

Analgesics, Opioid
Animals
Conditioning, Classical
Male
Melatonin
Morphine
Rats
Rats, Wistar

Chemicals

Analgesics, Opioid
Morphine
Melatonin

Word Cloud

Created with Highcharts 10.0.0morphinepreferencemelatoningroupreceivedinjectioncontrolplaceMelatoninrats+sessionIPfoursessions30minconditionedpainmanagementHoweverpotentialopioidsattenuatesmelatonergicsystemWistardaysinitialvehicleplaced45-minchamber5 mg/kgtotalposttestCPPsinglemorphine-seekingbehaviormorphine-inducedPURPOSE:Morphinepredominantlyuseddrugpostoperativecancerabuseprimarydisadvantageusingneurohormonesynthesizedpinealglandinvolvedcircadianrhythmsmammalswellphysiologicalfunctionsprovenlyalcohol-seekingrelapsebehaviorsThereforeaimedinvestigateinvolvementattenuatingdependenceMATERIALSANDMETHODS:Maledividedthreegroups:Animalshabituated3evaluatedFollowingassignedeverydayalternatingtwochambers8white8-dayperiodgroupsplacement50 mg/kgtestRESULTS:StatisticalanalysisrevealedrepeatedadministrationproducedsignificantincreasescorecomparedadministeredattenuatedreducedCONCLUSION:findingsprovidenovelevidenceroletargetmodulatingaddictionlocomotionmemory

Similar Articles

Cited By